Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer
Lung cancer is one of the leading cancers in Hong Kong, accounting for 26.4% of cancer mortality in 2018. Approximately 80% of the lung cancers are non-small cell lung cancer (NSCLC).